Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD)

Inclusion Criteria: * The subject is male or female outpatients age 18 to 65 years, inclusive * The subject meets DSM-IV criteria for Generalized Anxiety Disorder as determined by the MINI. * Sexually active female patients of childbearing potential must be practicing at least one or more the following methods of contraception during the study: intrauterine device (IUD), barrier method in combination with a spermicide, oral/hormonal contraception or abstinence. Female patients of childbearing potential must have a negative pregnancy test prior to receiving study drug. * Written informed consent must be obtained from the subject prior to study participation. * The subject is in good medical health or with chronic medical conditions which are currently stable. * No current abuse of alcohol or other substance. * The subject has a total score of 20 or more on the SIGH-A at screening. * The subject has a Clinical Global Impression (CGI) Severity score of 4 or more at screening. Exclusion Criteria: * The subject meets DSM-IV criteria for an Axis I diagnosis (other than GAD) as the primary diagnosis (i.e., schizophrenia, mood disorder, psychosis, anorexia nervosa) as determined by the MINI. * The subject is clinically judged by the investigator to be at risk for suicide or is acutely suicidal as objectively measured by the MINI and MSE. * The subject is clinically judged by the investigator to be at risk for homicide or is acutely homicidal as objectively measured by the MINI and MSE. * The subject has a psychiatric condition that would require inpatient, or partial psychiatric hospitalization. * Seizure disorders. * Significant history of medical disease (i.e. cardiovascular, hepatic (e.g. cirrhosis, hepatitis B or C) renal, gynecological, musculoskeletal, neurological, gastrointestinal, metabolic, hematological, endocrine, cancer with a metastatic potential or progressive neurological disorders) which could impair reliable participation in the trial or necessitate the use of medication not allowed by this protocol. * The subject is pregnant, planning to become pregnant, or nursing. If a subject becomes pregnant, she will be discontinued immediately and followed appropriately. * Concomitant therapy with another investigational drug, or participation in an investigational drug study within one month prior to entering this study. * Current psychotherapeutic treatment except for treatment with Specific Reuptake Inhibitor (SSRIs) medications which include: Fluoxetine (Prozac), Paroxetine (Paxil), Sertraline (Zoloft), Luvox (Fluvoxamine), and Citalopram. Potential subjects may remain on one of the SSRI medications provided that he or she has been on a stable dose for at least 4 weeks prior to entering this study; this dose remains stable throughout the remainder of this study; and it can be determined that this medication is not exacerbating the anxiety symptoms. * History of poor compliance or in the Investigator's judgment patients any subject whose treatment as an outpatient would be clinically contraindicated * The subject has attempted suicide one or more times within the past twelve months * The subject has a Structured Hamilton Depression Rating Scale (SIGH-D) score above 38 which suggests a moderate to severe clinical level of depressive symptoms